|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Definitions and diagnosis显示文摘 | Gert Van Assche Axel Dignass Julian Panes Laurent Beaugerie John Karagiannis Mathieu Allez Thomas Ochsenkühn Tim Orchard Gerhard Rogler Edouard Louis Limas Kupcinskas Gerassimos Mantzaris Simon Travis Eduard Stange | 2009 | Journal of Crohn’s and Colitis2009，，1： | 10 |
| 2 | Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis显示文摘AIM: To investigate the phenotype of inflammatory bowel disease associated with primary sclerosing cholangitis (PSC-IBD). METHODS: Data from 75 PSC-IBD patients evaluated in our tertiary center between 1963 and 2006 were collected and compared to 150 IBD patients without PSC, matched for sex, birth date, IBD diagnosis date and initial disease location regarding ileal, different colonic segments, and rectum, respectively. RESULTS: While PSC-IBD patients received more 5-aminosalicylates (8.7 years/patient vs 2.9 years/ patient, P < 0.001), they required less immuno-suppressors (24% vs 46% at 10 years; P < 0.001) and less intestinal resection (10% vs 44% at 10 years, P < 0.001). The 25-year cumulative rate of colectomy was 25.1% in PSC-IBD and 37.3% in controls (P = 0.004). The 25-year cumulative rate of colorectal cancer was 23.4% in PSC-IBD vs 0% in controls (P = 0.002). PSC was the only independent risk factor for the development of colorectal cancer (OR = 10.8; 95% CI, 3.7-31.3). Overall survival rate without liver transplantation was reduced in PSC-IBD patients (67% vs 91% in controls at 25 years, P = 0.001).CONCLUSION: This study confirms that patients with PSC-IBD have a particular disease phenotype independent of the initial disease location. Although their disease is less active and they use more 5-aminosalicylates, they present a higher risk of colorectal cancer. | Harry Sokol Jacques Cosnes Olivier Chazouilleres Laurent Beaugerie Emmanuel Tiret Raoul Poupon Philippe Seksik | 2008 | World Journal of Gastroenterology2008，14，22： | 10 |
| 3 | Clinical,serological and genetic predictors of inflammatory bowel disease course显示文摘Patients with extensive or complicated Crohn's disease(CD) at diagnosis should be treated straightaway with immunosuppressive therapy according to the most recent guidelines.In patients with localized and uncomplicated CD at diagnosis,early use of immunosuppressive therapy is debated for preventing disease progression and limiting the disabling clinical impact.In this context,there is a need for predictors of benign or unfavourable subsequent clinical course,in order to avoid over-treating with risky drugs those patients who would have experienced spontaneous mid-term asymptomatic disease without progression towards irreversible intestinal lesions.At diagnosis,an age below 40 years,the presence of perianal lesions and the need for treating the first flare with steroids have been consistently associated with an unfavourable subsequent 5-year or 10-year clinical course.The positive predictive value of unfavourable course in patients with 2 or 3 predictors ranges between 0.75 and 0.95 in population-based and referral centre cohorts.Consequently,the use of these predictors can be integrated into the elements that influence individual decisions.In the CD postoperative context,keeping smoking and history of prior resection are the stron-gest predictors of disease symptomatic recurrence.However,these clinical predictors alone are not as reliable as severity of early postoperative endoscopic recurrence in clinical practice.In ulcerative colitis(UC),extensive colitis at diagnosis is associated with unfavourable clinical course in the first 5 to 10 years of the disease,and also with long-term colectomy and colorectal inflammation-associated colorectal cancer.In patients with extensive UC at diagnosis,a rapid step-up strategy aiming to achieve sustained deep remission should therefore be considered.At the moment,no reliable serological or genetic predictor of inflammatory bowel disease clinical course has been identified. | Laurent Beaugerie Harry Sokol | 2012 | World Journal of Gastroenterology2012，18，29： | 8 |
| 4 | Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study显示文摘 | Laurent Beaugerie Nicole Brousse Anne Marie Bouvier Jean Frédéric Colombel Marc Lémann Jacques Cosnes Xavier Hébuterne Antoine Cortot Yoram Bouhnik Jean Pierre Gendre Tabassome Simon Marc Maynadié Olivier Hermine Jean Faivre Fabrice Carrat | 2009 | The Lancet . 2009 (9701)2009，，： | 4 |
| 5 | Safety and Efficacy of Antigen-Specific Regulatory T-Cell Therapy for Patients With Refractory Crohn’s Disease显示文摘 | Pierre Desreumaux Arnaud Foussat Matthieu Allez Laurent Beaugerie Xavier Hébuterne Yoram Bouhnik Maria Nachury Valérie Brun Hervé Bastian Nathalie Belmonte Michel Ticchioni Agnès Duchange Patricia Morel–Mandrino Virginie Neveu Nathalie Clerget–Chossat Mig | 2012 | Gastroenterology2012，，5： | 4 |
| 6 | Second European evidence-based consensus on the diagnosis and management of ulcerative colitis: Special situations显示文摘 | Gert Van Assche Axel Dignass Bernd Bokemeyer Silvio Danese Paolo Gionchetti Gabriele Moser Laurent Beaugerie Fernando Gomollón Winfried H?user Klaus Herrlinger Bas Oldenburg Julian Panes Francisco Portela Gerhard Rogler Jürgen Stein Herbert Tilg Simon Tra | 2012 | Journal of Crohn’s and Colitis2012，，： | 4 |
| 7 | Saccharomyces boulardii Does Not Prevent Relapse of Crohn’s Disease显示文摘 | Arnaud Bourreille Guillaume Cadiot Gérard Le Dreau David Laharie Laurent Beaugerie Jean–Louis Dupas Philippe Marteau Patrick Rampal Dominique Moyse Ashraf Saleh Marie–Emmanuelle Le Guern Jean–Paul Galmiche | 2013 | Clinical Gastroenterology and Hepatology2013，，8： | 3 |
| 8 | Gender differences in the response of colitis to smoking显示文摘 | Jacques Cosnes Isabelle Nion-larmurier Pauline Afchain Laurent Beaugerie Jean-pierre Gendre | 2004 | Clinical Gastroenterology and Hepatology2004，，： | 2 |
| 9 | 低剂量白细胞介素-2在11种自身免疫疾病中的免疫学和临床疗效:单中心开放临床试验显示文摘背景调节性T(Tregs)细胞可以预防自身免疫并控制炎症,在各种自身免疫性或自身炎症性疾病中的研究都表明Treg细胞不足。由于低剂量白细胞介素-2(low-dose interleukin-2,ld-IL2)能够扩增并激活Tregs细胞,因此ld-IL2具有广泛的治疗潜力。目的我们通过一项临床试验观察ld-IL2治疗11种自身免疫性疾病中1种的效果,旨在评估ld-IL2的治疗潜力并选择疾病,以用于进一步的临床开发。方法本研究为前瞻开放性Ⅰ~Ⅱa期临床观察,入选了46例轻中度患者,诊断分别为类风湿关节炎、强直性脊柱炎、系统性红斑狼疮、牛皮癣、白塞病、肉芽肿性多血管炎、大动脉炎、克罗恩病、溃疡性结肠炎、自身免疫性肝炎或硬化性胆管炎。所有患者都接受了ld-IL2(100万IU/天)5天,然后每两周注射一次,维持6个月。所有患者均接受了深入的免疫监测和临床评估。结果在任何疾病类型以及任何合并药物治疗的患者中,ld-IL2都显示出了良好的耐受性。通过经典的免疫表型分析和广泛的免疫表型分析发现所有患者的Tregs细胞均被特异性地扩增激活,而效应T细胞没有被活化,提示ld-IL2具有临床疗效的前景。结论本研究中所采用的IL-2剂量和治疗方案可以选择性地激活和扩增Tregs细胞,并且对于不同的疾病种类以及不同的合并用药都是安全的。这一临床疗效以及初步结果可以为ld-IL2在各种自身免疫和自身炎症性疾病中开展Ⅱ期临床试验观察疗效提供了依据。试验注册号NCT01988506. | Michelle Rosenzwajg Roberta Lorenzon Patrice Cacoub Hang Phuong Pham Fabien Pitoiset Karim El Soufi Claire RIbet Claude Bernard Selim Aractingi Beatrice Banneville Laurent Beaugerie Francis Berenbaum Julien Champey Olivier Chazouilleres Christophe Corpechot Bruno Fautrel Arsfene Mekinian Elodie Regnier David Saadoun Joe-Elie Salem Jeremie Sellam Philippe Seksik Anne Daguenel-Nguyen Valene Doppler Jeremie Mariau Eric Vicaut David Klatzmann 杨新蕾(译) 张卓莉(校) | 2019 | 英国医学杂志中文版2019，22，2： | 2 |
| 10 | Crypt abscess-associated microbiota in inflammatory bowel disease and acute self-limited colitis显示文摘AIM:To evaluate whether crypt abscesses frominflammatory bowel disease(IBD)patients containbacteria and to establish their nature.METHODS:We studied 17 ulcerative colitis patients,11 Crohn's disease patients,7 patients with acute selflimited colitis(ASLC)and normal colonic biopsies from5 subjects who underwent colonoscopy for colon cancer screening.A fluorescent in situ hybridization techniquewas applied to colonic biopsies to assess the microbiotacomposition of the crypts and crypt abscesses.RESULTS:Crypts colonized by bacteria were observedin 42.9%and 3.6%of ASLC and IBD patients,respectively(P=0.019).Crypt abscesses colonized bybacteria were observed in 28.6%and 0.0%of ASLCand IBD patients,respectively(P=0.035).CONCLUSION:These results do not support thehypothesis that crypt abscesses in IBD are the resultof localized dysbiosis arising from persistence of livingbacteria colonizing the crypts. | Harry Sokol Nadia Vasquez Nadia Hoyeau-Idrissi Philippe Seksik Laurent Beaugerie Anne Lavergne-Slove Philippe Pochart Philippe Marteau | 2010 | World Journal of Gastroenterology2010，16，5： | 2 |
| 11 | Impact of cessation of smoking on the course of ulcerative colitis显示文摘 | Laurent Beaugerie Nathalie Massot Franck Carbonnel Stéphane Cattan Jean-Pierre Gendre Jacques Cosnes | 2001 | The American Journal of Gastroenterology2001，，7： | 2 |
| 12 | Smoking cessation and the course of Crohn’s disease: An intervention study显示文摘 | Jacques Cosnes Laurent Beaugerie Franck Carbonnel Jean-Pierre Gendre | 2001 | Gastroenterology2001，，： | 2 |
| 13 | Adaptive hyperphagia in patients with post-surgical malabsorption 显示文摘 | Cosnes J Lamy P Beaugerie L | 1990 | Gastroenterology1990，99，6： | 1 |
| 14 | Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease显示文摘 | Harry Sokol Laurent Beaugerie Marc Maynadié David Laharie Jean‐Louis Dupas Bernard Flourié Eric Lerebours Laurent Peyrin‐Biroulet Matthieu Allez Tabassome Simon Fabrice Carrat Nicole Brousse | 2012 | Inflamm Bowel Dis2012，，11： | 1 |
| 15 | Toxic effects of nonsteroidal anti-inflammatory drugs on the small bowel, colon, and rectum显示文摘 | Thiefin G Beaugerie L | 2005 | Joint Bone Spine2005，72，4： | 1 |
| 16 | Smoking cessation and the cours of Crohn's disease:an intervention study显示文摘 | Cosnes J Beaugerie L Carbonnel F | 2001 | Gastroenter- ology2001，120，5： | 1 |
| 17 | Lymphoproliferative disor- ders in patients receiving thiopurines for inflammatory bowel disease:a prospective observational cohort study 显示文摘 | Beaugerie L Brousse N Bouvier AM | 2009 | Lancet2009，374，9701： | 1 |
| 18 | Increased Risk of Acute Myeloid Leukemias and Myelodysplastic Syndromes in Patients Who Received Thiopurine Treatment for Inflammatory Bowel Disease显示文摘 | Anthony Lopez Morgane Mounier Anne-Marie Bouvier Fabrice Carrat Marc Maynadié Laurent Beaugerie Laurent Peyrin-Biroulet | 2014 | Clinical Gastroenterology and Hepatology2014，，： | 1 |
| 19 | The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Definitions and diagnosis显示文摘 | Gert Van Assche Axel Dignass Julian Panes Laurent Beaugerie John Karagiannis Mathieu Allez Thomas Ochsenkühn Tim Orchard Gerhard Rogler Edouard Louis Limas Kupcinskas Gerassimos Mantzaris Simon Travis Eduard Stange | 2009 | Journal of Crohn’s and Colitis2009，，1： | 1 |
| 20 | Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study显示文摘 | A. Bourrier F. Carrat J.‐F. Colombel A.‐M. Bouvier V. Abitbol P. Marteau J. Cosnes T. Simon L. Peyrin‐Biroulet L. Beaugerie | 2016 | Aliment Pharmacol Ther2016，，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员